Navigation Links
RNAi Gene Silencing System

Gene silencing by RNA interference (RNAi) in eukaryotic cell cultures requires double-stranded molecules known as short interfering RNA (siRNA). QIAGEN is a licensed supplier of siRNA, offering a custom siRNA oligonucleotide synthesis service, library siRNA directed against common target genes, and a Cancer siRNA Oligo Set for screening a large number of cancer-related genes using RNAi techniques. Features and benefits
  • siRNA synthesis using patented TOM-Amidite chemistry for high-coupling efficiency
  • High-purity siRNA for efficient gene silencing
  • Expert advice on siRNA design for maximizing gene-silencing potential
  • Labeled siRNA allowing transfection to be easily followed
  • siRNA is annealed and ready-to-use in cell transfection
Principle The application of RNAi to mammalian cells has revolutionized the field of functional genomics by allowing targeted inhibition of gene expression using double-stranded RNA (dsRNA) that carries the same sequence as mRNA transcribed from the target gene. In mammalian cell systems, double-stranded siRNA oligos can be used to induce gene silencing.

After siRNAs are delivered to the cytoplasm of a cell, they bind to a multi-protein complex to form an RNA-induced silencing complex (RISC). The siRNA-protein complex targets en dogenous mRNA whose sequence matches that of the siRNA. The RISC nuclease activity then cleaves the mRNAsiRNA duplex resulting in silencing of the target gene (see flowchart "siRNA-Mediated RNAi").

To target a specific gene by RNAi, a double-stranded siRNA containing the sense and antisense sequence of mRNA transcribed from the gene is required. QIAGEN provides expert advice on siRNA design. Patented TOM-Amidites are used to synthesize high-quality, high-purity, 21-nucleotide sense and antisense RNA oligonucleotides that are annealed to produce a duplex with symmetric 2-nucleotide 3'-end overhangs. Deprotected siRNA duplexes are desalted and purified to >97% purity by HPLC (ultrapure) or 80-85% (crude option). siRNA is supplied with a sterile resuspension buffer and is ready to use in transfection procedures.

Efficient Gene Silencing Using QIAGEN siRNA and TransMessenger Reagent Western blot of extracts from transfected HeLa-S3 cells probed with lamin A/C monoclonal primary antibodies. Cells were transfected using the indicated reagents. siRNA: short interfering RNA duplex targeting lamin A/C at position 608630 relative to the start codon; TM: TransMessenger Transfection Reagent; ODN: Scrambled 24mer oligodeoxynucleotide (control).

Applications
  • Repress expression of endogenous genes
  • Study of molecular and cellular processes
  • Target validation studies
  • Potential for gene therapy
Efficient, Targeted Gene Silencing Relative expression levels of lamin A/C after siRNA transfection. The value for the mock transfection was set as 1. Data were normalized to the expression level of GAPDH (internal control), which was quantified by real-time RT-PCR using Omniscript Reverse Transcriptase and the QuantiTect SYBR Green PCR Kit. Expression levels were calculated using a standard curve generated using different amounts of HeLa S3 cDNA. Data obtained under the indicated transfection conditions are shown as relative, normalized expression levels. Total RNA was prepared using the RNeasy Mini Kit and the QIAShredder homogenizer.



'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Quantification of siRNA Silencing Efficiency Using the LightCycler System
2. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
3. Drive Long-Term Silencing with CMV Vectors
4. Enhanced siRNA Delivery and Long-term Gene Silencing
5. Fast, Accurate Assessment of siRNA-induced Gene Silencing
6. Superior Gene Silencing Using Adenoviral Vectors
7. Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs
8. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
9. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
10. Your Data: Silencing Neural Cell Adhesion Genes with In Vitro Transcribed siRNAs
11. Your Data: Silencing of a Pro-apoptotic Transcription Factor Using Synthetic siRNA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):